ImaCor, Inc, the developer of the world’s only hemodynamic transesophageal echocardiography (hTEE™) technology, will be showcasing Zura EVO1™, its all-in-one platform for advanced hemodynamic management at three annual scientific meetings this month: EAST (Eastern Association for the Surgery of Trauma), SCCM (Society of Critical Care Medicine), and STS (Society of Thoracic Surgeons). This marks the premierdemonstration of the enhanced platform, a first-of-its-kind for hemodynamic management. The new capabilities are imaging features at 7 MHz and 18 cm depth, hemodynamic trending data of cardiac filling and function, and availability of a transthoracic echocardiography (TTE) probe for complementary hemodynamic management.
ImaCor’s all-in-one hemodynamic management platform offers hTEE, which is enabled by a miniaturized, disposable probe that can be left indwelling for up to 72 hours of direct continuous visualization. Most recently, a retrospective analysis at St. George’s Healthcare NHS Trust, London, UK, demonstrated that 195 hTEE evaluations resulted in the change of therapy of 41 patients, which ultimately improved hemodynamic parameters in 80.5% of patients. RV failure was diagnosed in almost 70% of patients, of which hTEE had a direct therapeutic impact in 68%. The study is available online at the Journal of Cardiothoracic and Vascular Anesthesia.
Dates and locations of these conferences:
EAST Annual Scientific Assembly
January 13-17, 2015
Disney's Contemporary Resort
Lake Buena Vista, FL
SCCM 44th Critical Care Congress
January 17-21, 2015
Phoenix Convention Center
STS 51st Annual Meeting
January 24-28, 2015
San Diego Convention Center
San Diego, CA
“Our customers are taking a disciplined approach to hemodynamics to help them manage their sickest patients, and we are committed to their successful implementations,” stated Peter Pellerito, President& CEO of ImaCor, Inc. “We provide programs that improve metrics like quality and cost while reducing risk for the patient and the hospital– in fact, we guarantee them.”
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare costs. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™ and ClariTEE® are trademarks of ImaCor, Inc. http://www.imacorinc.com.